
Luminescence (RLU)
1600
1400
1200
1000
800
600
400
200
0
P<0.05
No mAb
Rituximab
GE-Zilovertamab
Zilovertamab
No mAb
Rituximab
GE-Zilovertamab
Zilovertamab
MEC1
MEC1-ROR1

FIG. 1


P<0.01
Luminescence (RLU)
1400
1200
1000
800
600
400
200
0
No mAb
Rituximab
GE-Zilovertamab
Zilovertamab
No mAb
Rituximab
GE-Zilovertamab
Zilovertamab
MEC1
MEC1-ROR1

FIG. 2


Luminescence (RLU)
1400
1200
1000
800
600
400
200
0
P<0.05
No mAb
Rituximab
GE-Zilovertamab
Zilovertamab
No mAb
Rituximab
GE-Zilovertamab
Zilovertamab
MEC1
MEC1-ROR1

FIG. 3


% Specific Lysis
45
40
35
30
25
20
15
10
5
0
P<0.05
No mAb
Rituximab
GE-Zilovertamab
Zilovertamab
No mAb
Rituximab
GE-Zilovertamab
Zilovertamab
MEC1
MEC1-ROR1

FIG. 4


P<0.05
% Specific Lysis
45
40
35
30
25
20
15
10
5
0
No mAb
Rituximab
GE-Zilovertamab
Zilovertamab

FIG. 5


P<0.05
% Specific Lysis
45
40
35
30
25
20
15
10
5
0
No mAb
Rituximab
GE-Zilovertamab
Zilovertamab
No mAb
Rituximab
GE-Zilovertamab
Zilovertamab
NK92
NK92-CD16v

FIG. 6


% Specific Lysis
40
35
30
25
20
15
10
5
0
P<0.05
No mAb
Rituximab
GE-Zilovertamab
Zilovertamab

FIG. 7


P<0.01
% Specific Lysis
25
20
15
10
5
0
Target cells + + + + + +
Effector cells + + + + + +
IgG + – – + – –
GE-zilovertamab – + – – + –
Zilovertamab – – + – – +
MEC1
MEC1-ROR1

FIG. 8


P<0.05
P<0.05
30
25
20
15
10
5
0
% Specific Lysis
Target cells + + + + +
Effector cells + + + + +
Anti-CD16 – – + – +
IgG + – – – –
GE-zilovertamab – + + – –
Zilovertamab – – – + +
CLL cells

FIG. 9